Training Study to Characterise Biomarkers to the Engerix B Vaccine
It is thought that vaccines trigger innate inflammatory responses to induce antigenspecific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side effects. Currently there is a lack of reliable biomarkers (a measurable biological response that predicts something) able to predict severe inflammation and this has resulted in the development of several vaccines being terminated and the withdrawal of some licensed vaccines which were associated with inflammatory complications.
This study is part of the BIOVACSAFE project which is a 5year €30M project funded by the Innovative Medicine Initiative. The project involves a series of clinical studies using licensed vaccines as benchmarks to generate clinical data on inflammation and identify biomarkers that can be used to predict acceptable reactogenicity. The target is to identify biomarkers that can predict the occurrence of beneficial and detrimental effects in response to a vaccine. Such biomarkers could be used in future vaccine development programs to optimize selection of vaccine candidates with a profile that will be unlikely to generate worrisome safety signals once they are in generalized use.
This study is one in a series of "training" studies which will each use different licensed vaccines that are prototypical representatives of a class of vaccine used in a particular target population. Twenty four subjects will be randomised into two groups to receive: A) Engerix B vaccine (n = 20), B) Saline placebo (n = 4). Following a screening visit, participants will undergo two immunisations at month 0 and month 6. Each immunisation will occur during a seven day residential visit which will include immunization and intensive monitoring of physiological (e.g. heart rate, oral temperature, blood pressure) metabolic and immune (innate and adaptive) parameters. Both residential visits will be followed up by four outpatient visits with further monitoring and blood samples.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
|Official Title:||A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following the First and Third of Three Intra-muscular Immunisations With "Engerix B" Hepatitis B Vaccine or Saline Placebo in Healthy Adults With no Pre-existing Immunity to Hepatitis B|
- Change from baseline values of global gene expression in whole blood. [ Time Frame: Visits 1 (Day -28 to -2), 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21), 6 (Day 28), 7 (Day 168 to 173), 8 (Day 175), 9 (Day 182), 10 (day 189), 11 (Day 196). ] [ Designated as safety issue: No ]
- Proportion of subjects experiencing vaccine-related clinical events following administration of vaccine. [ Time Frame: Visits 2 (Day -1 to +5) , 3 (Day 7), 4 Day 14), 5 (Day 21), 6 (Day 28), 7 (Day 168 to 173), 8 (Day 175), 9 (Day 182), 10 (day 189), 11 (Day 196). ] [ Designated as safety issue: Yes ]
|Study Start Date:||February 2013|
|Estimated Study Completion Date:||January 2014|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Placebo Comparator: Placebo
Active Comparator: Vaccine
Engerix B vaccine
|Biological: Engerix B Vaccine|
|Contact: Julia Lawson||+44 800 269 firstname.lastname@example.org|
|Contact: Jennifer Stuart||+44 800 269 email@example.com|
|University of Surrey, Surrey CRC||Recruiting|
|Guildford, Surrey, United Kingdom, GU2 7XP|
|Principal Investigator: David J Lewis|